FDA approves Roche's Ocrevus Zunovo with Halozyme Enhanze delivery tech

By Yahoo! Finance | Sep 16, 2024 at 06:50 AM EST

Roche's Ocrevus Zunovo, utilizing Halozyme's Enhanze technology, received FDA approval for subcutaneous injection to treat multiple sclerosis. The new method offers flexibility and efficiency, with comparable safety and efficacy to the intravenous approach.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.